Several studies have revealed that ABCG2 as a biomarker of cancer stem-like cell (CSC) populations can limit the efficacy of chemotherapy and is a target for clinical interventions during the period of tumor relapse [2,3]. Here, ABCG2 is linked to neoplasm.